This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): fondaparinux sodium, Quixidar, GSK576428
Description: The antithrombotic activity of Arixtra is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa. By selectively binding to ATIII, Arixtra potentiates (about 300 times) the innate neutralization of Factor Xaby ATIII. Neutralization of Factor Xa interrupts the blood coagulation cascade and thus inhibitsthrombin formation and thrombus development.
Adolor and GlaxoSmithKline
In Sept 2004, GlaxoSmithKline acquired Arixtra for 297 pounds sterling, as part of the divestiture required from the merger of Sanofi and Aventis.
Adolor Corporation collaborates with GSK to sell Arixtra to surgeons throught its 30 person sales force. GSK pays Adolor at a full time equivalent (FTE) contract rate for the Adolor sales representatives.
Adolor and Cubist
In October 2011, Cubist Pharmaceuticals agreed to acquire Adolor. This acquisition closed in December 2011.
Aspen and GlaxoSmithKline
In September 2013, GlaxoSmithKline (GSK) announced it has reached an agreement to sell Arixtra and Fraxiparine brands (excluding China, India and Pakistan), and the Notre-Dame de Bondeville (NDB) manufacturing site to Aspen for 0.7 billion in cash, of which 0.1 billion relates to inventory. The net cash proceeds from the transaction after tax and transaction costs are expected to be approximately 0.6 billion. In...See full deal structure in Biomedtracker
Partners: Merck & Co., Inc. GlaxoSmithKline plc Aspen Pharmacare Holdings Limited
Pink Sheet Arixtra FDA Reviewers
Pink Sheet Arixtra Clinical Development
Pink Sheet Arixtra Clinical Protocols
Additional information available to subscribers only: